We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00540878
First Posted: October 8, 2007
Last Update Posted: May 18, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
GlaxoSmithKline
October 4, 2007
October 8, 2007
May 18, 2009
April 2007
Not Provided
AUC and CMAX after a single dose. [ Time Frame: after a single dose ]
Same as current
Complete list of historical versions of study NCT00540878 on ClinicalTrials.gov Archive Site
Safety and tolerability after single dose. [ Time Frame: after a single dose ]
Same as current
Not Provided
Not Provided
 
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
An Open-Label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400mg SB-751689 (a Calcium-Sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a single oral dose of each formulation, with five formulations of SB-751689 tested in total. Blood samples will be taken up to 24 hours postdose after each dose administration. This study will provide information for future possible formulation development of SB-751689 for Phase III.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Osteoporosis
Drug: SB-751689 oral tablets (400 mg)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
Not Provided
Not Provided

Inclusion criteria:

  • Healthy postmenopausal women; 40 and 65 years of age, inclusive
  • Non-smokers (as defined in exclusion criteria 6 below)
  • Body weight > or = 50 kg and BMI within the range 19-32 kg/m2
  • Capable of giving written informed consent and complying with the requirements and restrictions listed in the consent form

Exclusion criteria:

  • Any clinically relevant biological or physical abnormality found or reported at screening which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study
  • A QTc interval of > 450 msec at screening
  • Positive urine drug screen at screening
  • Positive urine test for alcohol at pre-dose
  • Positive for HIV or hepatitis B or C virus at screening
  • Urinary cotinine levels indicative of smoking at screening
  • History of smoking or use of nicotine containing products within one year of the study or >10 pack-year history of smoking overall
  • History of regular alcohol consumption exceeding 7 units/week (1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
  • History of drug abuse within 6 months of the study
  • Participation in a clinical study and received a drug or a new chemical entity with 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of the current study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs
  • Consumption of red wine, grapefruit, grapefruit juice or grapefruit containing products within 14 days prior to the first dose of study medication
  • Donation of blood in excess of 500 mL within 56 days prior to dosing
  • Evidence of renal, hepatic or biliary impairment
  • History of serious gastrointestinal disease
  • History of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History of clinically significant cardiovascular disease
  • Medical conditions that might alter bone metabolism
  • Serum parathyroid hormone (iPTH) test levels outside the reference range at screening
  • Liver function tests, parathyroid hormone test or CPK outside the reference range at screening
Sexes Eligible for Study: Female
40 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00540878
CR9108307
Not Provided
Not Provided
Not Provided
Study Director, GSK
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials, M.D. GlaxoSmithKline
GlaxoSmithKline
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP